CVS Caremark Makes Changes in Diabetes Coverage for 2025
Published: November 25th 2024 | Updated: November 25th 2024CVS Caremark has removed several diabetes drugs favor of newer products and generics, and is even favoring an insulin infusion system developed by a company that was cofounded by Alan Lotvin, a former executive at CVS Health.
Read More
FDA Clears Phase 2 Trial of Cannabis in PTSD
November 20th 2024After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More
ICER Gives Cell Therapy for Post-Transplant Complications High Rating
Published: October 31st 2024 | Updated: October 31st 2024ICER has given tabelecleucel a rating of A, indicating the T cell therapy for Epstein-Barr virus related post-transplant lymphoproliferative disease has a high certainty of substantial net health benefit and would be cost-effective if priced between $143,900 and $273,700.
Read More
The Link between GLP-1 Drugs and Diabetic Retinopathy Is Not So Clear | AAO 2024
Published: October 21st 2024 | Updated: October 21st 2024Clinical and other trials for GLP-1 therapies have found an association between these drugs and diabetic retinopathy complications in patients. But this could be an early worsening of disease unrelated to treatment.
Read More
CDC: Human Risk from H5N1 Bird Flu is Low | ID Week 2024
October 18th 2024The CDC’s Timothy M. Uyeki, M.D., cautioned, however, that if the virus changes, and especially if it begins to infect pigs, that would be a game changer, allowing the virus to mutate to one that is more of a threat to people.
Read More
Infection Continues to be Biggest Risk from Medical Tourism | ID Week 2024
October 17th 2024Recent outbreaks of infections related to procedures done outside the United States, such as the fungal meningitis outbreak last year related to cosmetic surgery in Mexico, demonstrate the risks of medical tourism.
Read More
Shifting Funding Priorities Could Mean More HIV Infections and Deaths | ID Week 2024
October 16th 2024The Centers for Disease Control and Prevention provides funding for HIV prevention for the populations at the highest risk of infection. State efforts to shift priorities could lead to poorer outcomes, more deaths and increased costs.
Read More